PepGen — Third Quarter 2026 Earnings Summary

PepGen reported positive top-line results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial, demonstrating a mean splicing correction of 46.5% and improvements in functional measures such as hand grip strength and mobility. The company has fully enrolled the third and highest dose cohort of 12.5 mg/kg, with results expected in the first half of 2027, while interim safety and clinical data for the FREEDOM-OLE study are anticipated in January 2027. Financially, PepGen recorded a net loss of $19.4 million for the quarter ended September 30, 2026, and maintains $104.8 million in cash and marketable securities sufficient to fund operations into 2028. The U.S. FDA has selected PGN-EDODM1 for its CMC Development and Readiness Pilot program to accelerate manufacturing alignment, though the FREEDOM2 study remains subject to a partial clinical hold pending further nonclinical data.